Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Akebia Therapeutics
(NQ:
AKBA
)
1.100
-0.050 (-4.35%)
Streaming Delayed Price
Updated: 1:59 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Akebia Therapeutics
< Previous
1
2
3
4
5
Next >
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
7 Biotech Stocks With Key Catalysts in March
March 09, 2022
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.
Via
InvestorPlace
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Akebia Therapeutics Earnings Perspective: Return On Capital Employed
March 03, 2022
Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
Recap: Akebia Therapeutics Q4 Earnings
March 01, 2022
Akebia Therapeutics (NASDAQ:AKBA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
7 Speculative Penny Stocks Worth a Roll of the Dice
February 25, 2022
Under any circumstance, penny stocks are extremely risky. However, their under-the-radar profile could be intriguing right now.
Via
InvestorPlace
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 04, 2022
Gainers Oncternal Therapeutics (NASDAQ:ONCT
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 30, 2021
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) stock moved upwards by 20.4% to $1.06 during Thursday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
Akebia Therapeutics, inc (AKBA) Q3 2021 Earnings Call Transcript
November 09, 2021
AKBA earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
August 20, 2021
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...
Via
Benzinga
Exposures
Product Safety
99 Biggest Movers From Yesterday
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript
August 05, 2021
AKBA earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Akebia Therapeutics Stock Is Soaring Today
August 05, 2021
Investors liked what they heard in the company's Q2 update.
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 16, 2021
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
July 15, 2021
Gainers Akebia Therapeutics (NASDAQ:AKBA...
Via
Benzinga
Akebia Therapeutics Insights: Return On Capital Employed
June 21, 2021
During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. In Q4, Akebia...
Via
Benzinga
Cramer Gives His Opinion On Novavax, Exact Sciences And More
June 08, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers Moderna Inc (NASDAQ: MRNA) over Novavax, Inc. (NASDAQ: NVAX). Philip Morris International Inc. (...
Via
Benzinga
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
June 04, 2021
Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the...
Via
Benzinga
Looking Into Akebia Therapeutics's Return On Capital Employed
June 01, 2021
During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. Akebia...
Via
Benzinga
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
June 01, 2021
Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 01, 2021
Gainers Paratek Pharmaceuticals (NASDAQ:PRTK) stock increased by 12.65% to $9.26 during Tuesday's pre-market session. The company's market cap stands at $434.5...
Via
Benzinga
Recap: Akebia Therapeutics Q1 Earnings
May 10, 2021
Shares of Akebia Therapeutics (NASDAQ:AKBA) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 4.26% year over...
Via
Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
28 Stocks Moving in Thursday's Pre-Market Session
April 29, 2021
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 39.6% to $9.23 in pre-market trading after the company disclosed updated data from its randomized, multicenter, placebo-...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.